InterShunt Technologies
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, InterShunt Technologies sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).
InterShunt Technologies: 1 sponsored US clinical trial, 1 recruiting.
InterShunt Technologies sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Ambulatory Heart Failure, NYHA Class IV, with 1 trials.
Mid-pack sponsor footprint
InterShunt Technologies is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
1 total, page 1 of 1
What is open in the InterShunt Technologies pipeline
1 recruiting of 1 indexed (100% open).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Ambulatory Heart Failure, NYHA Class IV (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
InterShunt Technologies: open-pipeline peers nationwide
Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
InterShunt Technologies sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this InterShunt Technologies page
1 registered trials is a research-attention snapshot, not an endorsement of InterShunt Technologies or any single study.
- 1 of InterShunt Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ambulatory Heart Failure, NYHA Class IV is the condition InterShunt Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ambulatory Heart Failure, NYHA Class IV trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. InterShunt Technologies pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.